 |
Ildong Pharmaceutical Group headquarters building in Seoul. (Photo courtesy of Ildong Pharmaceutical) |
[Alpha Biz= Kim Jisun] SEOUL, November 9, 2025 — Ildong Pharmaceutical Co., Ltd. announced that its board of directors has approved the sale of its entire stake in D&D Pharmatech, only one month after acquiring the shares through an in-kind transaction.
According to industry sources on Sunday, Ildong decided on November 6 to sell all 53,023 shares of D&D Pharmatech—equivalent to a 0.49% ownership stake—via open market transactions. The total sale value is estimated at ₩15.85 billion (approx. US $11.5 million), representing about 10% of the company’s equity capital (₩159.1 billion).
The divestment will take place gradually between November 7, 2025 and February 6, 2026, depending on market conditions.
D&D Pharmatech specializes in developing peptide-based drugs using its proprietary “ORALINK” platform, which enhances the oral absorption of peptide therapeutics. The company is conducting R&D on obesity, metabolic, and neurodegenerative disorders, and has recently licensed its ORALINK technology to U.S.-based obesity drug developer Metsera. The platform is viewed as a key enabler for converting GLP-1 (glucagon-like peptide-1) obesity treatments—currently injectable—into oral tablet formulations, a fast-growing global trend.
Ildong had acquired the stake on October 1 through the liquidation of the Qudus Family No. 3 New Technology Business Investment Fund, in which it had invested ₩3 billion (US $2.2 million) in 2021. Upon the fund’s termination, Ildong received D&D Pharmatech shares as part of an in-kind distribution, valued at ₩10.66 billion (₩201,000 per share) at that time.
Following a sharp rally in D&D Pharmatech’s share price over the past month, Ildong stands to realize a gain of approximately ₩5.2 billion, or about 49% in return, based on the company’s disclosed sale price of ₩299,000 per share.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
